Loading Events

IDEAYA Biosciences Phase 2 Clinical Data Update for IDE397 in MTAP-Deletion Urothelial and NSCLC

DATE: July 8, 2024

About The Event

Join IDEAYA Biosciences for an investor webcast to provide a clinical data update for the IDE397 Phase 2 monotherapy expansion dose in MTAP-deletion urothelial and non-small cell lung cancer (NSCLC) patients. IDE397 is a potent and selective potential first-in-class methionine adenosyltransferase 2 alpha (MAT2A) inhibitor in Phase 2 clinical trials for the treatment of methylthioadenosine phosphorylase (MTAP) deletion solid tumors.

The investor webcast presentation agenda to review the IDE397 clinical data update of the Phase 2 expansion dose results in MTAP-deletion urothelial and NSCLC patients will be the following:

  • Market introduction: U.S. annual incidence in MTAP-deletion solid tumors
  • IDE397 preclinical summary in MTAP-deletion
  • Patient baseline characteristics
  • Pharmacokinetics and pharmacodynamics
  • Adverse event profile
  • Clinical efficacy in 18 evaluable MTAP-deletion urothelial and NSCLC patients by RECIST 1.1
    • Overall Response Rate (%ORR) and Disease Control Rate (%DCR) analysis
    • Swimlane plot
    • ctDNA molecular response analysis
    • Case reports and CT-scan images

The IDEAYA speakers will include Yujiro S. Hata, Chief Executive Officer, Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, and Michael White, Ph.D., Chief Scientific Officer.